Clinical Trial Update: A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study of LYB004, a recombinant zoster vaccine produced in CHO cells, in adults aged 50 to 70; the trial is currently active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• LYB004 (recombinant zoster vaccine)

Snippet

Sponsor: Guangzhou Patronus Biotech Co., Ltd. | Conditions: Herpes Zoster | Phase 1 | Status: ACTIVE_NOT_RECRUITING